News Categories
Resources For Living
Mesothelioma Forum
Legal Help Blog
Find a Doctor Near You
Mesothelioma Blog
Latest News
- Mesothelin Finding Could Lead to Early Detection of Mesothelioma
- New York Attorney Calls for International Ban on Mesothelioma-Causing Asbestos
- Protein Can be Reliable for Diagnosing Malignant Mesothelioma
- Biomarker Successes Remain Elusive For Mesothelioma and Cancer Researchers
- Avastin May Not be Effective for Breast Cancer, But is Still an Option for Mesothelioma
- Options for Funding Mesothelioma Research
- Golf Outing to Raise Funds for Mesothelioma Research
- 3 Year Mesothelioma Survivor Stays Busy Raising Awareness of the Disease
- MesotheliomaHelp Website Offers Mesothelioma-Related FAQs
- CDMRP System Offers Funding Opportunity to Help Military Mesothelioma Sufferers
Tuesday, September 29, 2009
Eli Lilly and Co. announced this month that their drug Alimta has extended the life of lung cancer patients by about three months. The clinical trial findings were compared with patients who received the best treatment currently available and a placebo. The study was reported in The Lancet, a British medical journal.
Alimta is approved for treatment in non-squamous tumors which is about 70 percent of all lung cancers. The patients, when treated with Alimta, lived for 15.5 months as compared to 10.3 months for the patients receiving a placebo. Alimta is also approved as a treatment for mesothelioma.
Alimta is used as “maintenance therapy” on patients who have previously received chemotherapy and whose cancer has not progressed. The clinical trial was conducted on a group of 663 patients.
Labels: mesothelioma, Treatment News
posted by Nancy Meredith at 4:15 PM
